Positive new cost data on Novo Nordisk's Victoza

10 November 2015

New findings from a health economics and outcomes research (HEOR) analysis demonstrated that Victoza (liraglutide) 1.2mg is cost-effective for the treatment of type 2 diabetes in the UK market when compared to lixisenatide (Lyxumia from Sanofi) and is cost-saving compared to exenatide (Bydureon from AstraZeneca).

The favorable findings on Danish diabetes care giant Novo Nordisk’s (NOV: N) blockbuster Victoza were presented today at the 18th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) in Milan, Italy.

The analysis assessed the cost-effectiveness of liraglutide (1.2mg), exenatide (10mcg BID) and lixisenatide (20mcg), prescribed for the treatment of type 2 diabetes in the UK. Liraglutide (1.2mg) was found to be cost-effective versus lixisenatide, with an incremental cost-effectiveness ratio (ICER) of £7,367 ($7,956) per QALY; quality-adjusted life year) gained. Liraglutide (1.2mg) was associated with cost-savings of £87 versus exenatide 10mcg BID.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK